【摘 要】 目的 探討溫陽通脈協定方治療心陽虛衰型緩慢心律失常患者的療效。方法 將我院收治并確診的46例心陽虛衰型緩慢心律失常患者隨機分為兩組。對照組20例給予口服阿托品治療。而試驗組26例給予溫陽通脈協定方治療。比較兩組患者臨床療效的差異。同時評價患者對治療滿意度情況。結果 試驗組患者緩慢心律失常總有效率為92.3%顯著高于對照組60.0%,比較有統計學差異(P<0.05);試驗組患者治療滿意率96.2%顯著高于對照組60.0%,比較有統計學差異(P<0.05)。結論 溫陽通脈協定方治療心陽虛衰型緩慢心律失常療效顯著。其具有較高的臨床有效率。同時患者對治療滿意度也較高。進而提高患者生活質量及治療依從性,值得臨床選擇。
【關鍵詞】 溫陽通脈協定方;心陽虛衰型;緩慢心律失常;臨床分析
【中圖分類號】 R241.3 【文獻標識碼】 B
【Abstract】 Objective To observe the curative effect of Wenyangtongmai prescription in treatment of the patients with heart-yang deficiency and decline bradyarrhythmia.Method 46 cases in our hospital and were divided into two groups randomly.20 cases in the control group were given atropine while 26 patients in the test group were treated with Wenyangtongmai prescription.Result The total efficiency of test group was 92.3% was significantly higher than that in control group( 60%),the difference was statistically significant (P<0.05).The satisfaction rate of test group(96.2%)was significantly higher than that in control group(60%),the difference was statistically significant (P<0.05).Conclusion Wenyangtongmai prescription in treatment of the patients with heart-yang deficiency and decline bradyarrhythmia is worthy of clinical significant effect,Higher satisfaction and good treatment compliance.
【Keywords】 wenyangtongmai prescription;heart-yang;deficiency and decline;bradyarrhythmia;clinical analysis
緩慢心律失常是心臟疾病常見的癥狀之一[1,2]。其以心率緩慢,心室率低于60次/分鐘為特征。緩慢心律失常可見于各種器質性心臟病。其同時也見于自主神經功能失調的患者。臨床常見于竇性心動過緩及竇房傳導阻滯等。西醫目前尚無特效的治療方法。本研究觀察溫陽通脈協定方治療心陽虛衰型緩慢心律失常。其獲得較好的臨床療效,現報道如下:
1 資料與方法
1.1 一般資料 將2012年1月-2013年11月我院收治并確診的46例心陽虛衰型緩慢心律失常[3]患者隨機分為兩組。試驗組26例,男性16例,女性10例.年齡39-83歲,平均(62.4±4.9)歲;病程6個月-10年,平均(4.6±1.3)年;其中心室率40-45次/分鐘為5例。……